Opinion

Video

Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

Experts consider other pipeline treatments for non-muscle invasive bladder cancer (NMIBC), including new injectable options being explored.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      2 experts are featured in this series.
      Overcoming Challenges for Wider Adoption of TLX250
      1 expert is featured in this series.
      The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
      1 expert is featured in this series.
      Formulation Matters: Tailoring Abiraterone Dosing for Optimal Absorption and Tolerability
      2 experts are featured in this series.
      Lymph Node–Positive Kidney Disease: Future Implications of PET Imaging
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Immunotherapy in NMIBC: Key Results Safety Profile From BOND-003 Trial
      Topline Data From the BOND-003 Trial in NMIBC
      Topline Data From the BOND-003 Trial in NMIBC
      1 expert is featured in this series.
      Assessing Tolerability and Clinical Considerations in Abiraterone Formulation Selection
      1 expert is featured in this series.
      A 74-Year-Old Man With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
      3 experts are featured in this series.
      Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
      1 expert is featured in this series.
      Remaining unmet needs in diverse populations with mHSPC
      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.